Ertapenem Neurotoxicity in Hemodialysis Patients—Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review:

Wasim S. El Nekidy,Hazem Elrefaei,Terrence Lee St John,Nizar Attallah,Farah Kablaoui,Ahmad Nusair,Bartlomiej Piechowski-Jozwiak,Janise Phillips,Islam M. Ghazi

Ertapenem Neurotoxicity in Hemodialysis Patients—Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review:

2020

Wasim S. El Nekidy
Hazem Elrefaei
Terrence Lee St John
Nizar Attallah
Farah Kablaoui
Ahmad Nusair
Bartlomiej Piechowski-Jozwiak
Janise Phillips
Islam M. Ghazi

Background: The approved dosing of ertapenem in patients with chronic kidney disease stage 5 utilizing dialysis (CKD-5D) is 0.5 g intravenous daily. Several reports associated this dosing strategy ...

Keywords:

Retrospective cohort study
Dosing
Medicine
Anesthesia
Kidney disease
Diabetes mellitus
Neurotoxicity
Dialysis
Hemodialysis
Internal medicine
Ertapenem

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations